Optimer Pharmaceuticals (OPTR) Sees IPO Pricing Between $12-14
More News related to OPTR
- After-Hours Movers 2/4: PWER, OPTR, PTIX, HA, TSYS Higher; PWAV, TTMI, MFLX, SNCR, BMI Lower
- Optimer Pharmaceuticals (OPTR) Announces Positive Phase 3 Results
- Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infection
- Ladenburg Thalmann Upgrades Optimer Pharmaceuticals (OPTR) to Buy
- Notable Insider Trades 12/29 (LM, OPTR, MED, CTXS, AM, COST, more...)
In an amended S-1 filing with the SEC, Optimer Pharmaceuticals (Nasdaq: OPTR) announced the pricing of its initial public offering of Common Stock between $12-$14 per share. The shares will begin trading today on the NASDAQ Global Market under the symbol "OPTR".
The offering will consist of 5,250,000 shares of Common Stock and made through an underwriting syndicate including Piper Jaffray, JMP Securities, Jefferies & Company and Rodman & Renshaw.
OPTR is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products. The company's initial development efforts address products that treat gastrointestinal infections and related diseases where current therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. OPTR currently have two late-stage anti-infective product candidates, Difimicin and Prulifloxacin.
Related Categories
IPOsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
